Human vascular adhesion proteın-1 (VAP-1): Serum levels for hepatocellular carcinoma in non-alcoholic and alcoholic fatty liver disease
1 Department of General Surgery, Yuzuncu Yıl University Medical Faculty, Van, Turkey
2 Department of Biochemistry, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
3 Department of Gastroeneterology, Yuzuncu Yıl University Medical Faculty, Van, Turkey
4 Department of Biostatistics, Istanbul Medical Faculty, University of Istanbul, Istanbul, Turkey
5 II. General Surgery, Haseki Research and Education Hospital, Istanbul, Turkey
World Journal of Surgical Oncology 2010, 8:83 doi:10.1186/1477-7819-8-83Published: 17 September 2010
The incidence of hepatocellular cancer in complicated alcoholic and non-alcoholic fatty liver diseases is on the rise in western countries as well in our country. Vascular adhesion protein-1 (VAP-1) levels have been presented as new marker. In our study protocol, we assessed the value of this serum protein, as a newly postulant biomarker for hepatocellular cancer in patients with a history of alcoholic and non-alcoholic fatty liver diseases.
Pre-operative serum samples from 55 patients with hepatocellular cancer with a history of alcoholic and non-alcoholic fatty liver diseases and patients with cirrhosis were assessed by a quantitative sandwich ELISA using anti-VAP-1 mAbs. This technique is used to determine the levels of soluble VAP-1 (sVAP-1) in the serum.
sVAP-1 levels were evaluated in patients with hepatocellular cancer and liver cirrhosis. There was a significant difference in mean VAP-1 levels between groups. Serum VAP-1 levels were found higher in patients with hepatocellular cancer.
These findings indicate that the serum level of sVAP-1 might be a beneficial marker of disease activity in chronic liver diseases.